# Alzheimer's Association of Israel

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/alzheimer-s-association-of-israel/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56 |
| Citations | 57,691 |
| City | Ramat Gan |
| Country | IL |
| Description | Alzheimer's Association of Israel is a research organisation in Ramat Gan, IL. OpenAlex records 1,251 works and 57,691 citations for it. 505 researchers list it as their most recent affiliation. |
| Homepage | http://www.alz-il.net/lang/186-english-2 |
| OpenAlex ID | https://openalex.org/I4210160816 |
| Researchers | 505 |
| ROR ID | https://ror.org/0561tpp86 |
| Type | nonprofit |
| Works | 1,251 |

## University papers

Showing 12 of 16.

- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-semaglutide-compared-with-liraglutide-and-placebo-for/)
- [Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus](https://scholariq.org/papers/comparison-of-the-effects-of-glucagon-like-peptide-receptor-agonists-and-sodium/)
- [Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial](https://scholariq.org/papers/heart-failure-saxagliptin-and-diabetes-mellitus-observations-from-the-savor-timi/)
- [Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial](https://scholariq.org/papers/effects-of-dapagliflozin-on-development-and-progression-of-kidney-disease-in/)
- [Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-heart-failure-and-mortality-in-type-2-diabetes/)
- [Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-atrial-fibrillation-in-patients-with-type-2-diabetes/)
- [Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)

## University researchers

- [Ofri Mosenzon](https://scholariq.org/researchers/ofri-mosenzon/)

## University top topics

Showing 8 of 21.

- [Complex Systems and Time Series Analysis](https://scholariq.org/topics/complex-systems-and-time-series-analysis/)
- [Advancements in Battery Materials](https://scholariq.org/topics/advancements-in-battery-materials/)
- [Advanced Battery Materials and Technologies](https://scholariq.org/topics/advanced-battery-materials-and-technologies/)
- [Substance Abuse Treatment and Outcomes](https://scholariq.org/topics/substance-abuse-treatment-and-outcomes/)
- [Alcohol Consumption and Health Effects](https://scholariq.org/topics/alcohol-consumption-and-health-effects/)
- [Irrigation Practices and Water Management](https://scholariq.org/topics/irrigation-practices-and-water-management/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Cannabis and Cannabinoid Research](https://scholariq.org/topics/cannabis-and-cannabinoid-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.